The FlexISH assay brings flexibility to cytogenetic HER2 testing.

about

HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.

P2860

Q48147789-0AB68E24-9892-4F45-AB7D-51A77D737269 Q50070938-2ABCE48A-F7A8-438F-BD53-D76A7BA98700

P2860

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

Item

http://www.wikidata.org/entity/Q55026325

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@en

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@nl

type

Item

label

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@en

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@nl

prefLabel

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@en

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@nl

P1476

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

@en

P2093

Florian Zeman

http://www.w3.org/2001/XMLSchema#string

Gero Brockhoff

http://www.w3.org/2001/XMLSchema#string

Maria Bock

http://www.w3.org/2001/XMLSchema#string

Sven Hauke

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical methods for assessing agreement between two methods of clinical measurement

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.

P304

635-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HIS.12974

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27008983

http://www.w3.org/2001/XMLSchema#string

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

about

P2860

P2860

The FlexISH assay brings flexibility to cytogenetic HER2 testing.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698